Arthritis is the most prevalent cause of chronic morbidity among those over 65 years of age, with over 30 million Americans suffering from the various arthritedes. The actual cost of treating these orthopaedic conditions represents billions of dollars in health care costs. The cost in human suffering is impossible to quantify. Despite tremendous research efforts, our understanding of the etiology and pathogenesis of these diseases is still incomplete. This proposal is designed to utilize gene therapy to systematically study molecular questions about arthritis, as well as test new treatments for this disabling disease. Specifically, this project focuses on a novel anti- TNFalpha gene therapy protocol to treat the polyarthritis of the hTNFalpha-transgenic mouse. A current paradigm is that TNFalpha is at the apex of the pro- inflammatory cytokine cascade which is responsible for joint destruction in arthritis. At the cellular level, the transcription factor NFkappaB is of paramount importance because it is both directly involved in the transcription of many inflammatory cytokines genes like TNFalpha and is activated by cell stimulation with these proteins. In turn NFkappaB amplifies these stimuli by initiating the transcription of a large number of genes, including matrix metaloproteases (MMPs), which cause the pathology. Our hypothesis is that the TNFalpha/NFkappaB signal transduction pathway is central to the genesis of arthritis and by using a specific inhibitor of this pathway we will prevent the disease process. In our studies of NFkappaB signal transduction, we have generated a dominant-negative IkappaBa (mIkappaB) which represents the specific inhibitor we desire. When over-expressed in mammalian cells, the mIkappaB renders them void of NFkappaB activity. Here we propose the following specific aims: i) identify additional cytokines, adhesion molecules and MMPs which promote disease in the hTNFalpha-transgenic mouse, and determine their cellular source, ii) determine the efficiency of our recombinant adenovirus, adenoassociated virus (AAV) and lentivirus (HIV) vector systems to transduce the cells of the joint in vitro and in vivo; and to modify these vectors with specific promoters to achieve the desired tissue expression, iii) test the ability of our mIkappaB to eliminate NFkappaB gene expression and monitor this effect on anabolic and catabolic mechanisms relevant to joint homeostasis, and iv) evaluate the usefulness of our mIkappaB to treat the arthritis of the hTNFalpha-transgenic mouse by in vivo gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR045971-03
Application #
6375203
Study Section
Orthopedics and Musculoskeletal Study Section (ORTH)
Program Officer
Gretz, Elizabeth
Project Start
1999-09-20
Project End
2003-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
3
Fiscal Year
2001
Total Cost
$214,516
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Zhang, Xinping; Xie, Chao; Lin, Angela S P et al. (2005) Periosteal progenitor cell fate in segmental cortical bone graft transplantations: implications for functional tissue engineering. J Bone Miner Res 20:2124-37
Ulrich-Vinther, M; Duch, M R; Soballe, K et al. (2004) In vivo gene delivery to articular chondrocytes mediated by an adeno-associated virus vector. J Orthop Res 22:726-34
Tiyapatanaputi, Prarop; Rubery, Paul T; Carmouche, Jonathan et al. (2004) A novel murine segmental femoral graft model. J Orthop Res 22:1254-60
Wooley, P H; Schwarz, E M (2004) Aseptic loosening. Gene Ther 11:402-7
Schwarz, Edward M; Campbell, Debbie; Totterman, Saara et al. (2003) Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. J Orthop Res 21:1049-55
Yang, Shang-You; Mayton, Lois; Wu, Bin et al. (2002) Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum 46:2514-23
Ulrich-Vinther, Michael; Carmody, Emily E; Goater, J Jeffrey et al. (2002) Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am 84-A:1405-12
Ulrich-Vinther, Michael; Maloney, Michael D; Goater, J Jeffrey et al. (2002) Light-activated gene transduction enhances adeno-associated virus vector-mediated gene expression in human articular chondrocytes. Arthritis Rheum 46:2095-104
Goater, J Jeffrey; O'Keefe, Regis J; Rosier, Randy N et al. (2002) Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res 20:169-73
Zhang, Xinping; Schwarz, Edward M; Young, Donald A et al. (2002) Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109:1405-15

Showing the most recent 10 out of 19 publications